AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Topline results from Phase 3 EPCORE DLBCL‑4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression‑free survival (PFS) in patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL).
Topline results from the Phase 3 EPCORE DLBCL‑4 trial evaluating epcoritamab plus lenalidomide versus standard chemoimmunotherapy (R‑GemOx) in adult patients with relapsed or refractory Diffuse Large B‑cell Lymphoma demonstrated a statistically significant and clinically meaningful improvement in progression‑free survival.
These results represent a promising new therapeutic option for patients with relapsed or refractory DLBCL, a disease that historically carries limited treatment choices and poor outcomes.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report